Spatiotemporal regulation of de novo and salvage purine synthesis during brain development

The levels of purines, essential molecules to sustain eukaryotic cell homeostasis, are regulated by the coordination of the de novo and salvage synthesis pathways. In the embryonic central nervous system (CNS), the de novo pathway is considered crucial to meet the requirements for the active proliferation of neural stem/progenitor cells (NSPCs). However, how these two pathways are balanced or separately utilized during CNS development remains poorly understood. In this study, we showed a dynamic shift in pathway utilization, with greater reliance on the de novo pathway during embryonic stages and on the salvage pathway at postnatal–adult stages. The pharmacological effects of various purine synthesis inhibitors in vitro and the expression profile of purine synthesis enzymes indicated that NSPCs in the embryonic cerebrum mainly utilize the de novo pathway. Simulatenously, NSPCs in the cerebellum require both the de novo and the salvage pathways. In vivo administration of de novo inhibitors resulted in severe hypoplasia of the forebrain cortical region, indicating a gradient of purine demand along the anteroposterior axis of the embryonic brain, with cortical areas of the dorsal forebrain having higher purine requirements than ventral or posterior areas such as the striatum and thalamus. This histological defect of the neocortex was accompanied by strong downregulation of the mechanistic target of rapamycin complex 1 (mTORC1)/ribosomal S6 kinase (S6K)/S6 signaling cascade, a crucial pathway for cell metabolism, growth, and survival. These findings indicate the importance of the spatiotemporal regulation of both purine pathways for mTORC1 signaling and proper brain development.

[1]  S. Sakakibara,et al.  Inka2, a novel Pak4 inhibitor, regulates actin dynamics in neuronal development , 2022, bioRxiv.

[2]  C. Boeckx,et al.  Pathway-specific effects of ADSL deficiency on neurodevelopment , 2022, eLife.

[3]  F. Di Virgilio,et al.  From purines to purinergic signalling: molecular functions and human diseases , 2021, Signal Transduction and Targeted Therapy.

[4]  S. Sakakibara,et al.  Drp1 SUMO/deSUMOylation by Senp5 isoforms influences ER tubulation and mitochondrial dynamics to regulate brain development , 2021, bioRxiv.

[5]  S. Benkovic,et al.  Human de novo purine biosynthesis , 2020, Critical reviews in biochemistry and molecular biology.

[6]  Madeline G. Andrews,et al.  mTOR signaling regulates the morphology and migration of outer radial glia in developing human cortex , 2020, bioRxiv.

[7]  S. Benkovic,et al.  Metabolomics and mass spectrometry imaging reveal channeled de novo purine synthesis in cells , 2020, Science.

[8]  S. Sakakibara,et al.  Nwd1 Regulates Neuronal Differentiation and Migration through Purinosome Formation in the Developing Cerebral Cortex , 2019, bioRxiv.

[9]  S. Lyonnet,et al.  PAICS deficiency, a new defect of de novo purine synthesis resulting in multiple congenital anomalies and fatal outcome. , 2019, Human molecular genetics.

[10]  K. Nagata,et al.  Spatiotemporally Dependent Vascularization Is Differently Utilized among Neural Progenitor Subtypes during Neocortical Development. , 2019, Cell reports.

[11]  Yulong Yin,et al.  Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy , 2018, Front. Immunol..

[12]  S. Sakakibara,et al.  Expression profile of the STAND protein Nwd1 in the developing and mature mouse central nervous system , 2018, The Journal of comparative neurology.

[13]  G. Evans,et al.  Immucillins in Infectious Diseases. , 2017, ACS infectious diseases.

[14]  L. Nguyen,et al.  Cerebral cortex development: an outside‐in perspective , 2017, FEBS letters.

[15]  J. Asara,et al.  The mTORC1 Signaling Network Senses Changes in Cellular Purine Nucleotide Levels. , 2017, Cell reports.

[16]  R. Abraham,et al.  Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. , 2017, Cell reports.

[17]  R. Day,et al.  Allopurinol: insights from studies of dose–response relationships , 2017, Expert opinion on drug metabolism & toxicology.

[18]  S. Benkovic,et al.  A New View into the Regulation of Purine Metabolism: The Purinosome. , 2017, Trends in biochemical sciences.

[19]  F. Di Virgilio,et al.  Extracellular purines, purinergic receptors and tumor growth , 2016, Oncogene.

[20]  J. Asara,et al.  mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle , 2016, Science.

[21]  Ye Fang,et al.  Spatial colocalization and functional link of purinosomes with mitochondria , 2016, Science.

[22]  Christopher S. Bjornsson,et al.  It takes a village: constructing the neurogenic niche. , 2015, Developmental cell.

[23]  G. Condorelli,et al.  mTOR regulates brain morphogenesis by mediating GSK3 signaling , 2014, Development.

[24]  Stanislav Kmoch,et al.  Adenylosuccinate lyase deficiency , 2014, Journal of Inherited Metabolic Disease.

[25]  Rongkun Shen,et al.  Isl1 Directly Controls a Cholinergic Neuronal Identity in the Developing Forebrain and Spinal Cord by Forming Cell Type-Specific Complexes , 2014, PLoS genetics.

[26]  Shuichi Ueda,et al.  Radmis, a Novel Mitotic Spindle Protein that Functions in Cell Division of Neural Progenitors , 2013, PloS one.

[27]  N. Sonenberg,et al.  mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. , 2013, Cell metabolism.

[28]  D. Sabatini,et al.  mTOR Signaling. , 2012, Cold Spring Harbor perspectives in biology.

[29]  A. Rea-Rosas,et al.  Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome , 2010, American journal of medical genetics. Part A.

[30]  D. Hunter Rheumatic diseases clinics of North America. Preface. , 2008, Rheumatic diseases clinics of North America.

[31]  Stephen J Benkovic,et al.  Reversible Compartmentalization of de Novo Purine Biosynthetic Complexes in Living Cells , 2008, Science.

[32]  S. Goldman,et al.  Purinergic signaling regulates neural progenitor cell expansion and neurogenesis. , 2007, Developmental biology.

[33]  C. Englund,et al.  Pax6, Tbr2, and Tbr1 Are Expressed Sequentially by Radial Glia, Intermediate Progenitor Cells, and Postmitotic Neurons in Developing Neocortex , 2005, The Journal of Neuroscience.

[34]  A. Allison Mechanisms of action of mycophenolate mofetil , 2005, Lupus.

[35]  J. Golden,et al.  Neuronal migration in developmental disorders. , 2005, Journal of child neurology.

[36]  M. Vincent,et al.  AICA-ribosiduria: a novel, neurologically devastating inborn error of purine biosynthesis caused by mutation of ATIC. , 2004, American journal of human genetics.

[37]  G. Fishell,et al.  Combinatorial function of the homeodomain proteins Nkx2.1 and Gsh2 in ventral telencephalic patterning , 2003, Development.

[38]  H. Bito,et al.  Pax6 regulates granule cell polarization during parallel fiber formation in the developing cerebellum. , 2001, Development.

[39]  H. Jinnah,et al.  Lesch–Nyhan disease and the basal ganglia , 2000, Brain Research Reviews.

[40]  A. Lavdas,et al.  The Medial Ganglionic Eminence Gives Rise to a Population of Early Neurons in the Developing Cerebral Cortex , 1999, The Journal of Neuroscience.

[41]  B. Cronstein The mechanism of action of methotrexate. , 1997, Rheumatic diseases clinics of North America.

[42]  I. Fox Inborn errors of purine and pyrimidine metabolism. , 1976, Clinics of Perinatology.

[43]  W. Nyhan,et al.  A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. , 1964, The American journal of medicine.